The original survey in US (August 2020) on the impact of COVID-19 pandemic on clinical trials from clinical pharmacology perspective was sponsored by COVID-19 Working Group under the Clinical Pharmacology Leadership Group (CPLG) of IQ consortium. It collected data up to July 2020, approximately 4 months into the pandemic. The current survey was sponsored by IQ CPLG Japan Subteam in July 2021, focusing to collect data of companies’ experiences on changing timeline/study design/development strategy due to COVID-19 pandemic, which were specific in Japan. Since most of the late-stage clinical trials are global multi regional studies and covered by the original survey, our survey was limited to Phase 1 (clinical pharmacology), single center trials including Japanese subjects or patients. The survey questions were designed at trial level and composed of 10 quantitative questions and one case study. The survey results show that 1) most of the trials have been conducted in Japan; 2) changes were required in study design, e.g. prolonged admission period, COVID-19 PCR test; 3) remote Source Data Verifications (SDVs) were introduced, 4) limited site selection, e.g. reduced capacity and available regions. The overall impact on the study timeline and site selection were limited although some posted significant challenges prior to and during the trials. Companies have proactively addressed anticipated risk before protocol finalization and avoided significant impact on studies overall.